- Home
- FFIV vs INSM Comparison
FFIV vs INSM Comparison
Compare FFIV & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIV
- INSM
- Stock Information
- Founded
- FFIV 1996
- INSM 1988
- Country
- FFIV United States
- INSM United States
- Employees
- FFIV N/A
- INSM N/A
- Industry
- FFIV Computer Communications Equipment
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- FFIV Telecommunications
- INSM Health Care
- Exchange
- FFIV Nasdaq
- INSM Nasdaq
- Market Cap
- FFIV 14.8B
- INSM 14.3B
- IPO Year
- FFIV 1999
- INSM 2000
- Fundamental
- Price
- FFIV $264.45
- INSM $76.06
- Analyst Decision
- FFIV Hold
- INSM Strong Buy
- Analyst Count
- FFIV 10
- INSM 16
- Target Price
- FFIV $289.00
- INSM $95.36
- AVG Volume (30 Days)
- FFIV 588.3K
- INSM 1.6M
- Earning Date
- FFIV 04-28-2025
- INSM 05-08-2025
- Dividend Yield
- FFIV N/A
- INSM N/A
- EPS Growth
- FFIV 31.07
- INSM N/A
- EPS
- FFIV 10.05
- INSM N/A
- Revenue
- FFIV $2,890,012,000.00
- INSM $363,707,000.00
- Revenue This Year
- FFIV $9.02
- INSM $30.31
- Revenue Next Year
- FFIV $4.01
- INSM $118.39
- P/E Ratio
- FFIV $26.26
- INSM N/A
- Revenue Growth
- FFIV 3.02
- INSM 19.17
- 52 Week Low
- FFIV $159.01
- INSM $21.92
- 52 Week High
- FFIV $313.00
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- FFIV 39.33
- INSM 44.82
- Support Level
- FFIV $270.36
- INSM $76.05
- Resistance Level
- FFIV $278.85
- INSM $79.12
- Average True Range (ATR)
- FFIV 6.89
- INSM 2.52
- MACD
- FFIV 0.25
- INSM -0.05
- Stochastic Oscillator
- FFIV 39.40
- INSM 32.39
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.